Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM2 | Q9P1W9 | 18/20 | 0.49 |
| ▸ | PIM1 | P11309 | 17/20 | 0.47 |
| ▸ | PIM3 | Q86V86 | 16/20 | 0.47 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CFTR | P13569 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15880422 | 0.87 | PIM2 (0.41) | PIM2PIM1PIM3ALDH1A1 | |
| SCHEMBL318994 | 0.82 | PIM2 (0.48) | PIM2PIM1PIM3 | |
| SCHEMBL15873065 | 0.82 | ATR (0.49) | PIM2PIM1PIM3 | |
| SCHEMBL29552760 | 0.79 | GAA (0.40) | PIM2ALDH1A1CFTRHSD17B10 | |
| SCHEMBL319079 | 0.79 | CFTR (0.49) | PIM2PIM1PIM3ALDH1A1CFTR | |
| SCHEMBL28362597 | 0.79 | GAA (0.40) | PIM2ALDH1A1CFTRHSD17B10 | |
| SCHEMBL327143 | 0.78 | PIM2 (0.37) | PIM2PIM1PIM3IRAK4ALDH1A1 | |
| SCHEMBL18259555 | 0.77 | MAPT (0.52) | PIM2PIM1PIM3 | |
| SCHEMBL28043843 | 0.77 | NPSR1 (0.47) | IRAK4ALDH1A1CFTRHSD17B10 | |
| SCHEMBL9939101 | 0.77 | NQO2 (0.39) | PIM2IRAK4ALDH1A1CFTRHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150315150-A1 | KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2015-11-05 | — | — | US | disclosed |
| US-20150315150-A1 | KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2015-11-05 | — | — | US | disclosed |
| US-20150315150-A1 | KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2015-11-05 | — | — | US | disclosed |
| EP-2344474-B1 | PICOLINAMIDE DERIVATIVES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2015-09-23 | — | — | EP | disclosed |
| US-9079889-B2 | Kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2015-07-14 | — | — | US | disclosed |
| US-9079889-B2 | Kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2015-07-14 | — | — | US | disclosed |
| US-9079889-B2 | Kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2015-07-14 | — | — | US | disclosed |
| CN-101679266-B | PIM kinase inhibitors and methods of their use | NOVARTIS AG | 2015-05-06 | — | — | CN | disclosed |
| CN-104311480-A | Picolinamide derivatives as kinase inhibitors | NOVARTIS AG | 2015-01-28 | — | — | CN | disclosed |
| CN-102203079-B | Pyridine carboxamide derivatives as kinase inhibitors | NOVARTIS AG | 2014-12-10 | — | — | CN | disclosed |
| US-20120134987-A1 | KINASE INHIBITORS AND METHODS OF THEIR USE | BURGER MATTHEW T (US) | 2012-05-31 | — | — | US | disclosed |
| US-20120134987-A1 | KINASE INHIBITORS AND METHODS OF THEIR USE | BURGER MATTHEW T (US) | 2012-05-31 | — | — | US | disclosed |
| WO-2012004217-A1 | CYCLIC ETHER COMPOUNDS USEFUL AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-01-12 | — | — | WO | disclosed |
| EP-2344474-A1 | PICOLINAMIDE DERIVATIVES AS KINASE INHIBITORS | Novartis AG (CH) | 2011-07-20 | — | — | EP | disclosed |
| WO-2010026124-A1 | PICOLINAMIDE DERIVATIVES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2010-03-11 | — | — | WO | disclosed |
| US-20100056576-A1 | Kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2010-03-04 | — | — | US | disclosed |
| US-20100056576-A1 | Kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2010-03-04 | — | — | US | disclosed |
| US-20100056576-A1 | Kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2010-03-04 | — | — | US | disclosed |
| EP-2132177-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | Novartis Ag (CH) | 2009-12-16 | — | — | EP | disclosed |
| WO-2008106692-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120134987-A1 | KINASE INHIBITORS AND METHODS OF THEIR USE | PIM1, PIM2, PIM3 | PIM2 2/4885PIM1 1/4885PIM3 3/4885 |
| US-20100056576-A1 | Kinase inhibitors and methods of their use | PIM1, PIM2, PIM3 | PIM2 2/4885PIM1 1/4885PIM3 3/4885 |
| US-20150315150-A1 | KINASE INHIBITORS AND METHODS OF THEIR USE | PIM1, PIM2, PIM3 | PIM2 2/4885PIM1 1/4885PIM3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.